Investor Presentaiton
sanofi
First PCV21 pediatric vaccine extends protection against disease
Serotype composition per vaccine
IPD incremental coverage
rate in all ages¹
1 3 4 5 6A 6B 7F 9V 14 18C 19A 19F 23F 22F 33F 8 10A 11A 12F 15B 9N 2 17F 20
33F 8 10A1
Sanofi PCV21
Pfizer PCV20
Merck PCV15
Pfizer PCV13
27%
NVT/Others
37%
5%
PCV21 non PCV20
6%
31%
PCV20 non PCV15
17%
14%
9%
PCV15 non PCV13
26%
29%
PCV13 non PCV10
US
2019+2020
EU
2019+2020
NVT: Non-vaccine type NT: Non-typable IPD: Invasive pneumococcal disease
1. All age groups - US ABC data and ECDC Surveillance Atlas 2. Internal model 3. Tiley KS, J Infect Dis 2022; Plainvert C, Infect Dis Now 2022; Ekinci E, Front in Pediatr 2021.
61 Vaccines Investor Event
Significant residual burden
in U.S. pediatrics < 5 years²
~1,500 cases IPD
1.5m Acute Otitis Media cases
- 270k cases of pneumonia
9N serotype provides ~5-7%
pts gain in IPD coverage
across all ages1,3View entire presentation